ZFIN ID: ZDB-FISH-150901-26522
Fish name: vu12Tg
Genotype: vu12Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by vu12Tg
No data available
GENE EXPRESSION
Gene expression in vu12Tg
RNA expression
Expressed Gene Structure Conditions Figures
alcama standard conditions Fig. 2 from Chung et al., 2013
cdkn1bb standard conditions Fig. 4 from Kim et al., 2012
cdkn1ca standard conditions Fig. 4 from Kim et al., 2012
disc1 standard conditions Fig. 4 with image,  Fig. 6 with image from Boyd et al., 2015
chemical treatment: Cyclopamine Fig. 6 with image from Boyd et al., 2015
fabp7a standard conditions Fig. 2 from Kim et al., 2008
fzd8a standard conditions Fig. 1 with image from Kim et al., 2008
gad1b standard conditions Fig. 5 with image from Bae et al., 2009
gad2 standard conditions Fig. 5 with image from Bae et al., 2009
gfap standard conditions Fig. 2 with image from Park et al., 2007
gria4a standard conditions Fig. 1 from Piller et al., 2021
id2b standard conditions Fig. 4 from Kim et al., 2012
id4 standard conditions Fig. 4 from Kim et al., 2012
irx3a standard conditions Fig. 2 with image from Kim et al., 2008
isl2a standard conditions Fig. 3 with image from Kim et al., 2008
Fig. 4 with image from Shin et al., 2007
chemical treatment: DAPT Fig. 4 with image from Shin et al., 2007
kif11 standard conditions Fig. 10 with image from Johnson et al., 2014
mbpa standard conditions Fig. 1 with image from Takada et al., 2010
Fig. 5 with image from Bae et al., 2009
Fig. 2 with image from Park et al., 2007
chemical treatment: pharmaceutical Fig. 1 with image from Takada et al., 2010
neurog1 standard conditions Fig. 3 with image from Borodovsky et al., 2009
nkx2.2a standard conditions Fig. 8 with image from Scott et al., 2020
Fig. 2 with image from Kim et al., 2008
nkx6.1 standard conditions Fig. 8 from Zannino et al., 2009
pcna standard conditions Fig. 3 with image from Park et al., 2007
pkd2l1 standard conditions Fig. 8 from Djenoune et al., 2014
prdm8 standard conditions Fig. 1 from Scott et al., 2020
prdm12b standard conditions Fig. 1 with image from Zannino et al., 2014
prkci standard conditions Fig. 4 with image from Park et al., 2007
pvalb7 standard conditions Fig. 5 with image from Bae et al., 2009
qki2 standard conditions Fig. 4 from Kim et al., 2012
sim1a standard conditions Fig. 3 with image from Borodovsky et al., 2009
slc17a6b standard conditions Fig. 5 with image from Bae et al., 2009
sox2 standard conditions Fig. 4 with image from Snyder et al., 2012
sox5 standard conditions Fig. 4 from Kim et al., 2012
sox6 standard conditions Fig. 4 from Kim et al., 2012
sox10 standard conditions 21 figures with image from 14 publications
chemical treatment: drug Fig. 5 with image from Kim et al., 2008
sulf2a standard conditions Figure 7 with image from Danesin et al., 2021
tcf4 standard conditions Fig. 4 from Kim et al., 2012
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab1-aldoc standard conditions Fig. 2 with image from McFarland et al., 2008
Ab1-mnx1 standard conditions Fig. 5 with image from Almeida et al., 2016
Ab1-rps6 standard conditions Fig. 1 from Mathews et al., 2016
Fig. 4 from Kearns et al., 2015
Ab18-h3 standard conditions Fig. 5 with image from Almeida et al., 2016
Ab4-sox10 control Fig. 5 from Kim et al., 2015
zn-8 standard conditions Fig. 3,  Fig. 6 from Zannino et al., 2009
Fig. 3 with image from Kim et al., 2008
Ab1-tuba standard conditions Fig. 3 with image from Yang et al., 2015
Ab1-calb2 standard conditions Fig. 2 with image from McFarland et al., 2008
Ab4-sox10 chemical treatment: metronidazole, chemical treatment: sulfasalazine Fig. 5 from Kim et al., 2015
Ab2-isl standard conditions Fig. 4 with image from Snyder et al., 2012
Fig. 3,  Fig. 6 from Zannino et al., 2009
Ab1-prkcz control Fig. 7 with image from Takada et al., 2011
Ab1-fabp7 standard conditions Fig. 2,  Fig. 3 from Kim et al., 2008
Ab1-pax2 standard conditions Fig. 8 from Zannino et al., 2009
Ab-G3G4 chemical treatment: 5-bromo-2'-deoxyuridine Fig. 4 with image from Kim et al., 2008
Ab-3A10 standard conditions Fig. 5 with image from Almeida et al., 2016
Fig. 1 from Mathews et al., 2014
Ab20-mapk standard conditions Fig. 1 from Mathews et al., 2016
ab1-lhx3/4 standard conditions Fig. 2 with image from Seredick et al., 2014
Ab1-elavl chemical treatment: drug Fig. 1 with image from Takada et al., 2010
Fig. 5 with image from Kim et al., 2008
Ab1-dhrs12la standard conditions Fig. 1 with image from Nagarajan et al., 2019
zrf-1 standard conditions Fig. 3 with image from Hudish et al., 2013
Fig. 7 with image from Takada et al., 2011
Fig. 1 with image from Takada et al., 2010
Fig. 8 from Zannino et al., 2009
Fig. 6 with image from Kim et al., 2008
Fig. 4 with image,  Fig. S1 with image from Kim et al., 2008
Ab1-pvalb standard conditions Fig. 2 with image from McFarland et al., 2008
Ab20-mapk chemical treatment by environment: Ro 48-8071 Fig. 1 from Mathews et al., 2016
Ab1-rps6 chemical treatment: sirolimus Fig. 1 from Mathews et al., 2016
Fig. 4 from Kearns et al., 2015
Ab1-elavl standard conditions Fig. 2 with image from Shin et al., 2012
Fig. 1 with image from Takada et al., 2010
Fig. 5 with image from Bae et al., 2009
Fig. 8 from Zannino et al., 2009
Fig. 5 with image from Kim et al., 2008
Fig. 2 with image from McFarland et al., 2008
zrf-1 chemical treatment: DAPT Fig. 1 with image from Takada et al., 2010
Fig. 6 with image from Kim et al., 2008
Ab1-fabp7a fabp7a standard conditions Fig. 2 from Kim et al., 2008
Ab3-sox2 sox2 standard conditions Fig. 4 with image from Snyder et al., 2012
Ab2-sox10 sox10 standard conditions Fig. 1 from Piller et al., 2021
Ab1-sox10 standard conditions 16 figures with image from 10 publications
Ab1-sox10 chemical treatment: drug Fig. 1 with image from Takada et al., 2010
Fig. 5 with image from Kim et al., 2008
PHENOTYPE
Phenotype in vu12Tg
Phenotype Conditions Figures
cholesterol biosynthetic process process quality, abnormal chemical treatment: Ro 48-8071 Fig. 7 from Mathews et al., 2014
glioblast (sensu Vertebrata) cell migration in hindbrain decreased occurrence, abnormal chemical treatment: Cyclopamine Fig. 7 with image from Boyd et al., 2015
hindbrain glioblast (sensu Vertebrata) disc1 expression decreased amount, abnormal chemical treatment: Cyclopamine Fig. 6 with image from Boyd et al., 2015
hindbrain glioblast (sensu Vertebrata) EGFP expression decreased amount, abnormal chemical treatment: Cyclopamine Fig. 6 with image,  Fig. 7 with image from Boyd et al., 2015
hindbrain glioblast (sensu Vertebrata) disc1 expression decreased distribution, abnormal chemical treatment: Cyclopamine Fig. 6 with image from Boyd et al., 2015
hindbrain glioblast (sensu Vertebrata) EGFP expression decreased distribution, abnormal chemical treatment: Cyclopamine Fig. 6 with image,  Fig. 7 with image from Boyd et al., 2015
oligodendrocyte mislocalised dorsally, abnormal chemical treatment: atorvastatin Fig. 4 from Mathews et al., 2014
oligodendrocyte MAPK cascade decreased occurrence, abnormal chemical treatment by environment: Ro 48-8071 Fig. 1 from Mathews et al., 2016
oligodendrocyte TOR signaling decreased occurrence, abnormal chemical treatment: sirolimus Fig. 4 from Kearns et al., 2015
oligodendrocyte TOR signaling decreased occurrence, abnormal chemical treatment by environment: Ro 48-8071 Fig. 1 from Mathews et al., 2016
oligodendrocyte development process quality, abnormal chemical treatment: GGTI-2133 Fig. 5 from Mathews et al., 2014
oligodendrocyte development process quality, abnormal chemical treatment: atorvastatin Fig. 4 from Mathews et al., 2014
oligodendrocyte development process quality, abnormal chemical treatment: lonafarnib Fig. 5 from Mathews et al., 2014
oligodendrocyte differentiation disrupted, abnormal chemical treatment: Cyclopamine Fig. 7 with image from Boyd et al., 2015
oligodendrocyte progenitor proliferation disrupted, abnormal chemical treatment: Cyclopamine Fig. 7 with image from Boyd et al., 2015
protein farnesylation process quality, abnormal chemical treatment: lonafarnib Fig. 5 from Mathews et al., 2014
protein geranylgeranylation process quality, abnormal chemical treatment: GGTI-2133 Fig. 5 from Mathews et al., 2014
retina neuroblast (sensu Vertebrata) proliferative, abnormal chemical treatment: pharmaceutical Fig. 8 from Kassen et al., 2009
smoothened signaling pathway involved in ventral spinal cord patterning decreased process quality, abnormal chemical treatment: Cyclopamine Fig. 7 with image from Al Oustah et al., 2014
spinal cord has fewer parts of type oligodendrocyte, abnormal chemical treatment: Cyclopamine Fig. 7 with image from Al Oustah et al., 2014
spinal cord central nervous system myelination process quality, normal chemical treatment: GGTI-2133 Fig. 5 from Mathews et al., 2014
spinal cord dorsal side has fewer parts of type oligodendrocyte, abnormal chemical treatment by environment: trichostatin A Fig. 5 with image from Nagarajan et al., 2019
spinal cord oligodendrocyte adjacent to dorsal longitudinal fasciculus, normal chemical treatment: Ro 48-8071 Fig. 7 from Mathews et al., 2014
spinal cord oligodendrocyte ab1-rps6 labeling decreased amount, abnormal chemical treatment by environment: Ro 48-8071 Fig. 1 from Mathews et al., 2016
spinal cord oligodendrocyte ab1-rps6 labeling decreased amount, abnormal chemical treatment: sirolimus Fig. 4 from Kearns et al., 2015
spinal cord oligodendrocyte ab20-mapk labeling decreased amount, abnormal chemical treatment by environment: Ro 48-8071 Fig. 1 from Mathews et al., 2016
spinal cord oligodendrocyte dorsal to dorsal longitudinal fasciculus, abnormal chemical treatment: GGTI-2133 Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte dorsal to dorsal longitudinal fasciculus, abnormal chemical treatment: lonafarnib Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte far from dorsal longitudinal fasciculus, abnormal chemical treatment: atorvastatin Fig. 4 from Mathews et al., 2014
spinal cord oligodendrocyte mislocalised dorsally, abnormal chemical treatment: lonafarnib Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte mislocalised dorsally, abnormal chemical treatment: GGTI-2133 Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte position, normal chemical treatment: Ro 48-8071 Fig. 7 from Mathews et al., 2014

CITATIONS  (76)

Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.